By Melanie Senior
Matt Emmens, CEO of Shire Pharmaceuticals Group PLC , described last year's acquisition of Transkaryotic Therapies Inc. (TKT) as...
Shire: Remodeling Specialty Pharma
Listen to this article
As biotech and Big Pharma invade spec pharma's traditional in-licensing ground, Shire's challenge is to bring investors along with its necessary strategic evolution. They've succeeded so far. Other spec pharma firms should take note of how.
Candid conversations with C-suite leaders.
More from Business Strategy
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
- • By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.